Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767655 | 0.93 | EDNRB (0.57) | EDNRBEDNRA | |
| SCHEMBL4766273 | 0.92 | EDNRB (0.61) | EDNRBEDNRA | |
| SCHEMBL4769531 | 0.92 | EDNRB (0.63) | EDNRBEDNRA | |
| SCHEMBL4764929 | 0.91 | EDNRB (0.59) | EDNRBEDNRA | |
| SCHEMBL4792865 | 0.90 | EDNRA (0.57) | EDNRBEDNRA | |
| SCHEMBL4774538 | 0.89 | EDNRB (0.59) | EDNRBEDNRA | |
| SCHEMBL4771556 | 0.85 | EDNRB (0.59) | EDNRBEDNRA | |
| SCHEMBL5524119 | 0.83 | EDNRB (0.67) | EDNRBEDNRA | |
| SCHEMBL4764814 | 0.82 | EDNRB (0.64) | EDNRBEDNRA | |
| SCHEMBL4767169 | 0.82 | EDNRB (0.57) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2002837-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-17 | — | — | EP | claimed |
| EP-2002837-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |